{"id":496094,"date":"2020-07-15T13:40:02","date_gmt":"2020-07-15T13:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496094"},"modified":"2020-07-15T13:40:02","modified_gmt":"2020-07-15T13:40:02","slug":"abscess-market-size-epidemiology-leading-companies-drugs-population-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/abscess-market-size-epidemiology-leading-companies-drugs-population-and-competitive-analysis-by-delveinsight_496094.html","title":{"rendered":"Abscess Market Size, Epidemiology, Leading Companies, Drugs, Population and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Abscess<\/a><\/p>\n
\n
\u201cAbscess Market Insights, Epidemiology, and Market Forecast-2030\u201d<\/div>\n<\/div>\n<\/div>\n

DelveInsight has launched a new report on “Abscess – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

 <\/p>\n

DelveInsight’s “Abscess – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/strong>“<\/strong> report delivers an in-depth understanding of the Abscess , historical and forecasted epidemiology as well as the Abscess market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

 <\/p>\n

Reports key facts- <\/strong><\/p>\n

    \n
  1. In the United States, the estimated incidence of pyogenic liver abscess (PLA) based on a nationwide inpatient sample database was 3.6 cases per 100,000 population per year.<\/li>\n
  2. According to DelveInsight’s Analysis, age-adjusted incidence of PLA for men was 3.92 cases per 100,000 person-years compared with 1.87 cases per 100,000 person-years for women.<\/li>\n
  3. According to DelveInsight’s estimates, the incidence of brain abscess to be 0.3–0.9 per 100,000 inhabitants per year in developed countries, with a male-to-female sex ratio of 2: 1 to 3: 1, and a median age of 30–40 years.<\/li>\n
  4. The risk of brain abscess is estimated at 5–9% in patients with hereditary hemorrhagic telangiectasia, <5% in patients with infective endocarditis overall (7% in critically ill patients) and 0.2% after cranial surgery.<\/li>\n<\/ol>\n

     <\/p>\n

    Request for Sample Page: https:\/\/www.delveinsight.com\/sample-request\/abscess-market<\/a><\/strong><\/p>\n

     <\/p>\n

    Scope of the Report:<\/strong><\/p>\n